Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing

This study has been terminated.
(Closed incomplete due to Artes Medical Closing)
Information provided by:
Suneva Medical, Inc. Identifier:
First received: October 21, 2008
Last updated: March 19, 2010
Last verified: March 2010
The purpose of this study is to assess the clinical utility of the ArteFill® pre-treatment Skin Test in predicting and preventing hypersensitivity reactions to treatment with ArteFill® implant

Condition Intervention Phase
Device: ArteFill® Skin Test
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Open-Label Study to Evaluate the Immunogenicity of Bovine Collagen in ArteFill® by Skin Testing

Resource links provided by NLM:

Further study details as provided by Suneva Medical, Inc.:

Primary Outcome Measures:
  • Safety will be assessed by determination of a positive hypersensitivity reaction to the skin test and collection of adverse events. [ Time Frame: 60 days ]

Secondary Outcome Measures:
  • In addition to the primary outcome measure, to assist in assessing the etiology of the reaction, the immune response to the skin test in subjects with positive skin test will be evaluated by measuring serum antibody levels against bovine collagen. [ Time Frame: 60 days ]

Enrollment: 498
Study Start Date: July 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: ArteFill® Skin Test
    Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
Detailed Description:
This is a single-center, open-label study in approximately 485 healthy male and female subjects to obtain 450 evaluable subjects. In this protocol, an ArteFill® Skin Test study will be conducted to evaluate the test's clinical utility to determine the incidence of positive skin reactions to ArteFill®. The results of this skin test study will determine if the risk of a hypersensitivity reaction against ArteFill® without a skin test is no greater than the published historical risk of a hypersensitivity reaction against a Zyderm or Zyplast treatment after a patient demonstrates a negative response to a single Zyderm skin test. Based on prior clinical experience with ArteFill® implant in commercial use outside the United States, it is anticipated that no reactions will be observed. As such, it may be suggested that there is no practical use of the ArteFill® Skin Test for screening patients, and therefore, the test may be eliminated as a requirement prior to treatment with the ArteFill® product as is the clinical practice outside the United States.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects 18 years of age or older, male or female.
  • Subjects who are healthy and have normal skin on the volar surface of the forearm.
  • Subjects willing and able to comply with the requirements of the study.
  • Subjects willing and able to comply with the follow-up requirements.
  • Subjects willing and able to give written and verbal informed consent.

Exclusion Criteria:

  • Subjects who are pregnant, nursing or intend to become pregnant.
  • Subjects who have had any form of collagen soft tissue treatment within the last 12 months.
  • Subjects who were or are currently being treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids (including inhaled or insufflated) within the past 3 months.
  • Subjects who were or are currently being treated with any topical OTC drug or prescription therapy on their arms (below the elbow) within the past 3 months.
  • Subjects with a history indicative of abnormal immune function (e.g. auto- immune diseases, HIV, cancer, etc).
  • Subjects with known lidocaine hypersensitivity.
  • Subjects with known sensitivity to bovine collagen.
  • Subjects who have a history of dietary beef allergy, undergoing desensitization to beef products or planning to undergo desensitization within the study evaluation period.
  • Subjects with severe allergies manifested by a history of anaphylaxis.
  • Subject is currently enrolled in an investigational drug or device study.
  • Subject has received an investigational drug or an investigational device within 30 days prior to entering this study.
  • Subject has any skin pathology or condition that could interfere with the evaluation of the treatment areas.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00778089

United States, Virginia
The Education & Research Foundation, Inc.
Lynchburg, Virginia, United States, 24501
Sponsors and Collaborators
Suneva Medical, Inc.
Principal Investigator: David C Wilson, M.D. The Education & Research Foundation, Inc.
  More Information

Responsible Party: Karon Morell, Sr. VP, Regulatory and Quality Affairs, Suneva Medical, Inc. Identifier: NCT00778089     History of Changes
Other Study ID Numbers: D82-3001-07
Study First Received: October 21, 2008
Last Updated: March 19, 2010

Keywords provided by Suneva Medical, Inc.:
skin test
Skin test prior to administration of ArteFill® implant

Additional relevant MeSH terms:
Immune System Diseases
Polymethyl Methacrylate
Vasodilator Agents
Antimutagenic Agents
Protective Agents
Physiological Effects of Drugs processed this record on April 26, 2017